RenovoRx to Present TIGeR-PaC Trial PK/PD Data; RenovoCath Sales Hit $1.1 M
RenovoRx’s pharmacokinetic and pharmacodynamic sub-study of the Phase III TIGeR-PaC trial, comparing intra-arterial versus intravenous gemcitabine delivery via RenovoCath, will be presented at the 2026 ASCO Annual Meeting. In the first full commercial year, RenovoCath sales reached $1.1 million, with repeat orders from multiple National Cancer Institute-designated centers.
1. Abstract Acceptance for ASCO Presentation
RenovoRx’s abstract E16463 detailing the PK/PD sub-study in the Phase III TIGeR-PaC trial has been accepted for presentation at the ASCO Annual Meeting May 29-June 2, with online publication scheduled for May 21. The presentation will highlight data on targeted intra-arterial gemcitabine delivery via RenovoCath versus intravenous administration.
2. Focus of Phase III PK/PD Sub-Study
The sub-study examines systemic gemcitabine levels and inactive metabolite concentrations, correlating these with CA 19-9 biomarker changes to assess potential improvements in drug distribution and therapeutic response. Researchers aim to demonstrate that intra-arterial delivery enhances local drug potency while reducing systemic toxicity and common chemotherapy side effects.
3. Early Commercial Traction
Commercial efforts in 2025 generated approximately $1.1 million in RenovoCath sales, driven by repeat purchases from multiple National Cancer Institute-designated centers. The growing customer base and institution adoption provide revenue momentum ahead of anticipated 2026 growth initiatives.
4. TAMP Platform Potential
RenovoCath is FDA-cleared for localized drug delivery and temporary vessel occlusion and is central to the company’s Trans-Arterial Micro-Perfusion (TAMP) platform. The intra-arterial gemcitabine combination holds orphan drug designation for pancreatic and bile duct cancers, offering seven years of exclusivity upon approval.